Superior sensing performance of multi-walled carbon nanotube-based electrodes to detect unconjugated bilirubin by Taurino, Irene et al.
Thin Solid Films 548 (2013) 546–550
Contents lists available at ScienceDirect
Thin Solid Films
j ourna l homepage: www.e lsev ie r .com/ locate / ts fSuperior sensing performance of multi-walled carbon nanotube-based
electrodes to detect unconjugated bilirubin
Irene Taurino a,⁎, Viviane Van Hoof b,c, Giovanni De Micheli a, Sandro Carrara a
a Laboratory of Integrated Systems, EPFL - École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
b Laboratory of Clinical Biochemistry, Antwerp University Hospital, Edegem, Belgium
c University of Antwerp, Wilrijk, Belgium⁎ Corresponding author. Tel.: +41 76 26 57 195; fax: +
E-mail addresses: irene.taurino@epﬂ.ch (I. Taurino), V
(V. Van Hoof), giovanni.demicheli@epﬂ.ch (G. De Micheli
(S. Carrara).
0040-6090/$ – see front matter © 2013 Elsevier B.V. All ri
http://dx.doi.org/10.1016/j.tsf.2013.09.015a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 November 2012
Received in revised form 30 August 2013
Accepted 5 September 2013
Available online 14 September 2013
Keywords:
Amperometric biosensors
Bilirubin
Screen printed electrodes
Albumin
Multi-walled carbon nanotubesThe direct electrochemical behaviour of bilirubin in the physio-pathological concentration range and at physio-
logical pH was investigated by cyclic voltammetry. Nanostructured electrodes with a thin ﬁlm of multi-walled
carbon nanotubes exhibited a higher sensing performance than bare electrodes. The detection limit obtained
with nanostructured electrodes (4.2 ± 0.1 μM) allows the detection of both normal and pathological levels of
bilirubin. Due to its sparse solubility in aqueous solvents, in human ﬂuids bilirubin is found in the form of soluble
complex with albumin. Therefore, the nanostructured-sensor response was studied in presence of different con-
centrations of this protein. A signal weakening was observed with increasing concentrations of albumin due to
the decrease of free bilirubin. Finally, bilirubindetectionwas tested at concentrations typical of newborn jaundice
(200–500 μM) and in the presence of normal albumin levels. A detection limit of 9.4 ± 0.3 μM was identiﬁed.
Since this value is below the minimum critical bilirubin concentration for newborns, our sensor, modiﬁed with
a thin ﬁlm of carbon nanotubes, could potentially be used for bilirubin detection in cases of newborn jaundice.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Bilirubin (BR) is a tethrapyrrole compound of bile. It is a brownish
yellow pigment, produced when the liver breaks down old red blood
cells. BR is a natural anti-oxidant in human blood [1]. Two main types
of BR are present in human ﬂuids: conjugated and unconjugated BR.
Conjugated BR forms a complex with gluconic acid, which renders it
water soluble. Unconjugated BR, instead, tends to bind to albumin [2].
Therefore, the amount of free unconjugated BR in serum depends on
the concentration of albumin and on the intrinsic ability of albumin to
bind BR. This binding is very important for the neutralisation of the
neurotoxic effect of free unconjugated BR.
An accurate quantiﬁcation of BR in body ﬂuids is important for
diagnostic and therapeutic purposes. The normal level of total BR in
the serum of adults ranges from 3.5 to 22.6 μM (0.2–1.3 mg/dl) [3].
Higher and lower concentrations are associated with certain diseases.
For instance, jaundice, caused by high BR levels in the blood, is associated
with gallbladder and liver diseases (e.g., cirrhosis, hepatitis), blood infec-
tion, transfusion reaction, or haemolytic diseases of the newborn (cell
destruction) [4]. Conversely, low levels of BR are associated with anae-
mia and coronary artery diseases [4]. If untreated, high concentrations
of unconjugated free BR in neonates can lead to brain damage (hearing41 21 69 34 225.
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ghts reserved.loss and “Kernicterus”, a potentially lethal syndrome [5]). Very often
pathological levels of BR are associated with the accumulation of its
oxidised form, a pigment called biliverdin (BV) [6]. Therefore, consider-
ing the diagnostic signiﬁcance of BR, the development of an inexpensive
device for its detection is of great interest.
There are several methods to determine the concentration of BR. It
can be measured by direct spectrophotometry [7] or by diazo reac-
tion [8]. However, the former method may be affected by the interfer-
ence of other proteins, and the pH-dependence of the latter could
partially compromise the measurement [9]. Colorimetric [10] and
ﬂuorometric analysis [11] can also be used to quantify this metabolite.
Amperometric detection is simpler and more convenient if compared
to the above-mentioned techniques. It can be performed by using the
BR oxidase (BODx) immobilised onto the electrode surface. BODx catal-
yses the oxidation of BR to BV. Unfortunately this enzyme is highly un-
stable. Some strategies have been employed to overcome this problem
(conductive polymers [12], mediators [13] and cross-linking agents
[14,15] as well as multilayer enzyme networks [13]). Alternatively, the
instability related to the enzymatic detection could be solved by
exploiting the spontaneous conversion of BR to BV, occurring once suit-
able potentials are applied.
BR is liposoluble at physiological conditions but poorly soluble in
laboratory aqueous solvents. Therefore, the electrochemistry of BR has
been investigated in detergents such as Tris Buffer [13,16] or in organic
solvents such as dimethyl sulfoxide (DMSO) [17], dimethyl formalde-
hyde [18] and room temperature ionic liquids [19]. To simulate the
physiological environment, some authors have also investigated the
Fig. 1. Fitting example of the two voltammetric peaks by using Gaussian curves and a cubic
baseline (BR concentration: 150 μM).
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works, a BR stock solution was prepared by dissolving it in a basic sol-
vent. Lower BR concentrations were subsequently obtained by dilution
in aqueous buffers.
Even if BR is an electroactive compound, the possibility of detecting
thismoleculewithin its normal concentration range and in the presence
of albumin is a problematic aspect of the development of a BR biosensor.
To this end, the modiﬁcation of electrodes with metal nanoparticles
and/or nanotubes has proven to be a powerful route to tune the sensor
performance [21]. Indeed, nanomaterials improve the electrodes' elec-
trocatalytic properties by increasing their active surface area and thanks
to their quantum size effect [21]. Among them, carbon nanotubes (CNTs)
are interesting components for the electrochemical transducers. CNTs
are graphene cylinders formed by rolling one or more graphene sheets,
resulting in single-walled (SW) ormulti-walled (MW)CNTs. SWCNTs are
found to exhibit metallic, semi-conducting or small-band-gap semicon-
ducting properties, depending on their diameter and chirality. MWCNTs
instead are mostly metallic since a single metallic layer results in an
entire tube displaying a metallic behaviour. Thus, MWCNTs are better
candidates for electrochemical applications [22]. The electrochemical
detection of BR with MWCNTs has been carried out in previous works,
but ferrocene was used as a mediator [16] and the experiments were
performed in the absence of albumin [16].
In the present work, we compare the electrochemical behaviour of
bare screen-printed electrodes (SPEs) in the presence or absence of a
ﬁlm of MWCNTs in order to detect physio-pathological concentrations
of unconjugated BR by cyclic voltammetry (CV). Furthermore, the re-
sponse of modiﬁed-SPE was studied in the presence of albumin up to
its normal level, and concentrations of BR complexed to albumin were
measured in the range typical of newborn jaundice.
2. Materials and methods
2.1. Chemicals
A dispersion of carboxyl group (−COOH) functionalized MWCNTs
(DropSens, Spain) was prepared as previously described [23]. The
dispersion was sonicated before use to guarantee homogeneity. Stock
solutions of BR (Sigma) were prepared in DMSO solvent (10 mM).
Phosphate buffered saline (PBS 10 mM pH 7.4) was used for dilutions
in the presence or absence of ﬁxed bovine albumin at concentrations
ranging from 0 to 30 mg/ml. PBS and albumin were purchased from
Sigma. Since BR is photosensitive, measurements were carried out in a
dark room.
2.2. Electrode preparation and electrochemical apparatus
Electrodes were nanostructured with MWCNT ﬁlms by casting
30.00 ± 0.12 μl of MWCNT-chloroform solution (six times 5.00 ±
0.02 μl) onto the working electrode of carbon paste SPEs (model DRP-
110) purchased from DropSens (Spain). Chloroform was allowed to
evaporate from this electrode in between two subsequent deposition
steps. The surface area of the working electrode was equal to 12.54
mm2. The counter electrode was also made of graphite, while the refer-
ence electrodewasmade of Ag AgCl. The electrochemistry of BRwas in-
vestigated by CV with a Versastat 3 potentiostat (Princeton Applied
Technologies). All the experiments were carried out under aerobic
conditions at room temperature. During the measurements, the three
electrodeswere coveredwith 100 μl of BR-containing solutions.Multiple
CVs were acquired using a potential window of−0.4 /+ 0.8 V at a scan
rate of 20 mV/s. BR concentrations ranging from 50 to 150 μMby 25 μM
steps were used. Electrodes with andwithout aMWCNT layer were test-
ed. Five multiple CVs were applied, alternating them until two subse-
quent voltammograms overlapped. The adsorption of BR onto a large
variety of carbon nanomaterials has been reported [24]. In addition, the
well-known adsorption of albumin to the electrodes could also affectthe electrochemical measurements [25]. For these two reasons, in be-
tween two subsequent measurements a cleaning procedure was
performed by applying potential pulses as reported in [26]. Brieﬂy, we
used 3000 fast potential pulses between −0.4 and +0.8 V, repeated 3
times, and 10 multiple CVs (potential window−0.4 /+ 0.8 V and scan
rate 100 mV/s).
The two anodic peak currents (Peak I and II) identiﬁed in the V cycle
of multiple CVs were used to calculate the sensing parameters. A cubic
baseline was subtracted to the voltammogram part (positive scan) be-
tween 0 and 700 mV. The Igor Pro (Wavemetrics,Lake Oswego, OR,
USA) software was employed to ﬁt the two peaks using Gaussians [27]
that well described their shapes. The peak positions and heights were
optimally ﬁtted by minimising the chi-square, as described in the pro-
gram package. A ﬂowchart of the adopted procedure is depicted in
Fig. 1. The sensitivity was calculated from the slope of the straight line
obtained from peak currents vs. BR concentration plot. Sensitivity was
normalised to the electrode area. The standard deviation δi
 
of a
voltammogram portion in PBS was taken as black signal. The detection
limit (LOD) was calculated according to the expression LOD = 3δi /S
[28] where S is the sensitivity in μA/mM.
3. Results and discussion
3.1. Electrolyte optimization
Among several possible strategies, the preparation of the BR stock
solution using NaOH was deemed unsuitable because of the rapid pre-
cipitation [29] and oxidation of BR. Solutions prepared with Tris Buffer
(0.05 M, pH 8.0, albumin 30 mg/ml) were also excluded since no peak
current could be measured with either bare or nanostructured elec-
trodes. DMSO, instead, was proved to be an efﬁcient solvent for BR. Di-
lutions with PBS 0.01 M allowed BR detection. They were stable for
hours with regard to both oxidation and precipitation processes. All
the solutions were prepared daily because of the characteristic BR
instability.
3.2. Cyclic voltammetry with bare and nanostructured SPEs
Cyclic voltammetry of BR by using bare SPEs and SPEs nanostruc-
tured with MWCNT thin ﬁlms revealed three oxidation processes. In
the investigated BR concentration range (50–150 μM), the ﬁrst oxida-
tion process (Peak I) appears at an average potential of 252.1 ±
3.3 mV and the second (Peak II) at 481.7 ± 2.0 mV. The positions of
the two peaks vary slightly in the presence or absence of a layer of
MWCNTs. The third process occurs at higher potentials and only with
MWCNT ﬁlm-based SPEs. All these oxidation processes were found to
Fig. 3. Current Peaks I and II at various BR concentrations by using bare SPEs (50, 75, 100,
125, 150 μM).
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have already shown [16,19]. Peaks I and II are attributed to the oxidation
of BR and of BV, respectively (Reactions 1 and 2).
bilirubin→
≈þ300 mV
−2e−
biliverdin ð1Þ
biliverdin→
≈þ500 mV
−2e−
purpurine ð2Þ
This assumption is supported by the disappearance of Peak I when a
BR solution exposed to light for a week is used. Fig. 2 shows the change
in colour from orange to green after this period of light exposure. Peak
III instead is still present in these working conditions. Indeed, the third
oxidation process is related to the purpurine oxidation to choletelin
(Reaction 3).
purpurine→
≈þ700 mV
−2e−
choletelin ð3Þ
Figs. 3 and 4 show the increase of the ﬁrst and of the second oxida-
tion peak currents with increasing BR concentration. The BR concentra-
tion range was selected between 50 and 150 μM because it covers the
human plasma levels of BR in many patho-/physiological condi-
tions [3,4]. The best electrochemical response was found when
MWCNT ﬁlm-cast electrodes, rather than bare SPEs, were used. The
highest peak currents were registered in the presence of MWCNTs
due to the larger electroactive area that derived from the introduction
of nanostructures as well as to the excellent catalytic activity of
MWCNTs [30]. When bare electrodes were used, the sensitivity and
the LOD, calculated with respect to either Peak I or II, remained almost
unvaried (Peak I: 6.6 ± 0.3 μA/(mM cm2) and 54.4 ± 2.7 μM; Peak II:
6.4 ± 0.1 μA/(mM cm2) and 56.1 ± 0.8 μM). Conversely, the sensing
values change with MWCNT ﬁlm-cast SPEs depending on whether
Peak I or II is used to calculate them. In addition, an improvement of
one order of magnitude for both sensitivity and LOD was registered
when nanostructures were used. The sensitivity and the LOD calculated
by using Peak I were 52.2 ± 2.4 μA/(mM cm2) and 6.9 ±0.3 μM, re-
spectively. The highest sensitivity (86.2 ± 2.4 μA/(mM cm2)), the
greatest linearity (R2 = 0.99) and the lowest LOD (4.2 ± 0.1 μM) were
obtained by monitoring the increase of Peak II. The lowest LOD value
obtained in this case makes it possible to detect BR at concentrations
within the physiological [3] as well as the pathological range, such as in
cases of acute and chronic diseases [4]. Considering these ﬁndings, the
following calculations were made with respect to Peak II, and nanostruc-
tured electrodes were used for the measurements.
Reproducibility of the MWCNT ﬁlm-based SPEs was studied. Five
SPEsweremodiﬁedwithMWCNT coatings by using the same procedure.Fig. 2. Disappearance of Peak I after a week of light exposure (BR concentration: 500 μM;
scan rate: 20 mV/s). In the top left picture change in colour from orange to green of the BR
solution after one week of light exposure due to the BR oxidation in BV.Peak potentials and currents (Peak II) remained approximately un-
changed. Indeed, for 150 μM BR, the average peak potential and the
average peak current from ﬁve measurements are 462.6 ± 9.3 mV and
1.8 ± 0.1 μA, respectively. Satisfactory results were obtained by calcu-
lating the average sensitivity and LOD with the relative standard error.
Values of 97.2 ± 4.8 μA/(mM cm2) and 3.7 ± 0.2 μM were obtained
for sensitivity and LOD, respectively.
3.3. Measurements in the presence of albumin
BR is present in body ﬂuids in two forms, water-soluble and water-
insoluble. Water-soluble BR is called conjugated BR, and water-
insoluble BR is called unconjugated BR. In human plasma, unconjugated
BR is transported bound to a protein carrier, i.e. albumin. The association
mechanism of BR with albumin can be described by the following ex-
pression (Reaction 4).
Afree þ BRfree K → A=BRcomplex ð4Þ
The relation between free albumin, free BR and their complex in
terms of concentrations can be expressed by the equilibrium constant
(Eq. (5)) [2].
K ¼
A=BRcomplex
h i
Afree
h i
BRfree
h i ð5ÞFig. 4. Current Peaks I and II at various BR concentrations by using MWCNT ﬁlm-cast SPEs
(50, 75, 100, 125, 150 μM).
Fig. 5. Calibration plots for the BR detection in the presence of the following albumin con-
centrations: 0, 1 (albumin–BR molar ratio range: 0.1–0.3) and 10 mg/ml (albumin–BR
molar ratio range: 1–3).
Table 1
Peak potential shift by increasing the albumin concentration and using a MWCNT
ﬁlm-based SPE.
Albumin concentration (mg/ml) Potential (mV)
0 483.7 ± 0.2
1 504.2 ± 0.7
5 520.7 ± 1.8
10 530.5 ± 1.3
30 545.1 ± 1.8
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BR complex, the concentration of the latter is almost equal to that of the
unconjugated BR. Therefore, Eq. (5) can be written as Eq. (6).
BRfree
h i
¼
BRunconjugated
h i
K Afree
h i
− BRunconjugated
h i  ð6Þ
Wemeasured the peak current response by increasing the concentra-
tion of albumin in solution.With a concentration of albumin of 1 mg/ml,
the sensitivity decreases almost three fold (30.8 ± 1.0 μA/(mM cm2))
and the LOD increases almost four fold (12.4 ± 0.4 μM). Hypoalbumin-
emia characterises certain pathologies such as renal disease, chronic
infections and inﬂammation. In these cases, patients show plasma albu-
min levels as low as 10 mg/ml [31]. By using this concentration of
albumin the sensing performance declines further (sensitivity: 21.8 ±
0.6 μA/(mM cm2); LOD: 23.3 ± 0.7 μM). Calibration curves for albumin
levels of 0, 1 and 10 mg/ml are shown in Fig. 5. The voltammetric
response of theMWCNTﬁlm-sensor becomes negligible for normal albu-
min concentration (30 mg/ml). However, the signal is still present even
if themolar ratio between BR and albumin is equal to 0.33. Other authors
[32] were unable to measure BR for BR/albumin molar ratios below 1.
The reduction of the peak current as a function of increasing albumin
concentrations at a ﬁxed BR amount (150 μM) is shown in Fig. 6. The
most evident drop in current occurs when passing from 0 mg/ml to
1 mg/ml of albumin concentration. When passing from 1 to 30 mg/ml
of albumin in solution, instead, the current decreases only slightly.
These ﬁndings indicate that the majority of BR binds to albumin when
1 mg/ml of the protein is added into the solution. By increasing theFig. 6. Current Peak II versus albumin concentration (albumin: 0, 1, 5, 10, 30 mg/ml; BR
concentration: 150 μM; albumin–BR molar ratios: 0.1, 0.5, 1, 3).protein concentration from 1 to 30 mg/ml, the amount of free BR re-
mains quite the same. This electrode behaviour is in agreement with
Eq. (6). However, the adsorption of serum albumin onto the different
electrodematerials [26] also plays a role in the decrease of the BR current
peaks.
Moreover, we noticed that the highest oxidation potentials were
registered when the albumin concentration was highest. This potential
shift is due to the fact that the more BR–albumin complex is present in
solution, themore the electron transfer kinetics decreases. Furthermore,
the highest potential shift was registered passing from an albumin con-
centration of 0 to 1 mg/ml (Table 1). This corresponds to the albumin
addition step at which the majority of the BR–albumin complex forms.3.4. Detection in newborn jaundice
An excessive amount of BR in the human body (jaundice) is
recognised in various diseases. In particular, the highest levels of BR
are found in babies with jaundice. Newborns usually have higher red
blood cell breakdown and their immature livers are not efﬁciently con-
jugating BR, and thus removal of BR from the bloodstream is delayed.
Clinically, untreated jaundice in neonates can lead to mental retarda-
tion, cerebral palsy, deafness and even death, due to the passage of
free BR through the blood–brain barrier [5]. Critical levels of un-
conjugated BR for healthy newborns are greater than 15 mg/dl
(≈250μM), and up to 30 mg/dl (≈500 μM), but are lower in prema-
ture babies. Fig. 7 shows the experimental calibration curve registered
with MWCNT ﬁlm-SPEs in the BR concentration range critical for new-
borns and in the presence of normal levels of albumin (30 mg/ml). A
linear relation between peak current and BR concentration was found
in the investigated range with the following regression equation: Ip
(μA/cm2) =3.79 [BR](mM), with a correlation coefﬁcient of 0.99. The
sensitivity and the LOD were determined to be 30.2 ± 0.8 μA/(mM
cm2) and 9.4 ± 0.3 μM, respectively. It should be noted that the LOD
is below theminimum critical BR value for newborns. As a consequence,
the sensor could be used to monitor the BR level in babies affected by
both acute and chronic newborn jaundice.Fig. 7. Calibration plot for the BR detection in the range 200–400 μM critical for neonatal
children (albumin concentration: 30 mg/ml).
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The BR electrochemistry has been investigated with SPEs in the
presence and absence of MWCNT layers in the BR physio-pathological
range (up to 150 μM). Three oxidation processes were recognised by
cyclic voltammetry. The ﬁrst two occur at ≈300 mV and ≈500 mV,
respectively. The last process appears at≈700 mVonly for high BR con-
centrations in solution. All these reactions were found to be highly
irreversible.
Comparing the sensing parameters, namely sensitivity and LOD, by
using both nanostructured and non-nanostructured SPEs, we found a
marked enhancement in the case of MWCNT ﬁlm-based electrodes. In
the range 0–150 μM of BR, monitoring the increase of Peak II gave the
highest sensitivity (86.2 ± 2.4 μA/(mM cm2)), the greatest linearity
and the lowest LOD (4.2 ± 0.1 μM). Interestingly, the LOD was found
to be low enough to detect BR down to the relative physiological
range. The increase of Peak II detected using MWCNT ﬁlm-based SPEs
was used for the following investigations.
The effect of albumin on the BR voltammetric response was also
studied. Mixtures of a ﬁxed BR concentration (150 μM) with increasing
albumin concentrations up to the relative normal valueswere prepared.
A reduction of the current signal was registered as well as a worsening
of the sensitivity and the LOD. This behaviour can be explained by the
decline of free BR as the albumin level increases. To a certain extent,
this phenomenon is inﬂuenced by the adsorption of albumin onto the
electrode surface [26]. However, BR has been detected at a BR/albumin
molar ratio smaller than 1.
Themeasurement of BR is of great interest for clinicians for the diag-
nosis and treatment of certain diseases. In particular, the highest BR
levels have been registered in neonatal jaundice (critical range:
200–500 μM) and are associated to permanent brain damages. There-
fore, experiments in this concentration range were performed with so-
lutions containing relative physiological levels (30 mg/ml) of albumin.
A LOD below the minimum critical BR concentration for newborns
was obtained (9.4 ± 0.3 μM). The experiments performed in the pres-
ence of various albumin concentrations indicate the possibility that
only free BR, the neurotoxic form of BR, is detectable by using the mod-
iﬁed sensor. Future developments of this work could be the electro-
chemical study of a panel of redox probes (cationic, anionic and
neutral) under various concentrations of albumin for an accurate elec-
trochemical characterisation of the modiﬁed electrodes.
Free unconjugated BR is an electroactive biocompound. In human
ﬂuids, BR is found in a water soluble complex with albumin. The BR–
albumin complex is not electroactive, therefore in the presence of al-
bumin only the BR that remains dissociated from albumin is oxidised
and reduced spontaneously at the electrode. This study proves the pos-
sibility of detecting free unconjugated BR only by nanostructuring elec-
trodes with MWCNT thin layers. The proposed sensor was used to
detect BR in the relative critical concentration range for newborn jaun-
dice, in the presence of albumin at levels typically found in human
serum. The adsorption of lipids and other proteins onto the electrodewill occur if serum is used as electrolyte. The decrease of the sensor
response in these experimental conditions is well-documented in the
literature [33]. Thereby, in order to gain fundamental insight about
the detection of BRwith the proposedmodiﬁed electrodes, future mea-
surements will be carried out by using serum as the support electrolyte.
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